Advanced SearchSearch Tips
Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : BMB Reports
  • Volume 49, Issue 2,  2016, pp.105-110
  • Publisher : Korean Society for Biochemistry and Molecular Biology
  • DOI : 10.5483/BMBRep.2016.49.2.173
 Title & Authors
Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice
Oh, Ah-Reum; Bae, Jin-Sik; Lee, Junghoon; Shin, Eunji; Oh, Byung-Chul; Park, Sang-Chul; Cha, Ji-Young;
  PDF(new window)
Ursodeoxycholic acid (UDCA), a natural, hydrophilic nontoxic bile acid, is clinically effective for treating cholestatic and chronic liver diseases. We investigated the chronic effects of UDCA on age-related lipid homeostasis and underlying molecular mechanisms. Twenty-week-old C57BL/6 male and female mice were fed a diet with or without 0.3% UDCA supplementation for 25 weeks. UDCA significantly reduced weight gain, adiposity, hepatic triglyceride, and hepatic cholesterol without incidental hepatic injury. UDCA-mediated hepatic triglyceride reduction was associated with downregulated hepatic expression of peroxisome proliferator-activated receptor-γ, and of other genes involved in lipogenesis (Chrebp, Acaca, Fasn, Scd1, and Me1) and fatty acid uptake (Ldlr, Cd36). The inflammatory cytokines Tnfa, Ccl2, and Il6 were significantly decreased in liver and/or white adipose tissues of UDCA-fed mice. These data suggest that UDCA exerts beneficial effects on age-related metabolic disorders by lowering the hepatic lipid accumulation, while concurrently reducing hepatocyte and adipocyte susceptibility to inflammatory stimuli.
Anti-inflammatory;Bile acid;Lipogenesis;Peroxisome proliferator-activated receptor-γ;Ursodeoxycholic acid;
 Cited by
Insulin Resistance, Microbiota, and Fat Distribution Changes by a New Model of Vertical Sleeve Gastrectomy in Obese Rats, Diabetes, 2016, 65, 10, 2990  crossref(new windwow)
Arlia-Ciommo A, Piano A, Svistkova V, Mohtashami S and Titorenko VI (2014) Mechanisms underlying the anti-aging and anti-tumor effects of lithocholic bile acid. Int J Mol Sci 15, 16522-16543 crossref(new window)

Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50, 1955-1966 crossref(new window)

Amador-Noguez D, Yagi K, Venable S and Darlington G (2004) Gene expression profile of long-lived Ames dwarf mice and Little mice. Aging Cell 3, 423-441 crossref(new window)

Amador-Noguez D, Dean A, Huang W, Setchell K, Moore D and Darlington G (2007) Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell 6, 453-470 crossref(new window)

Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y and Darnis F (1987) Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1, 834-836 crossref(new window)

Lazaridis KN, Gores GJ and Lindor KD (2001) Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 35, 134-146 crossref(new window)

Zollner G, Fickert P, Fuchsbichler A et al (2003) Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 39, 480-488 crossref(new window)

Trauner M, Meier PJ and Boyer JL (1998) Molecular pathogenesis of cholestasis. N Engl J Med 339, 1217-1227 crossref(new window)

Bellentani S (2005) Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur J Gastroenterol Hepatol 17, 137-140 crossref(new window)

Rodrigues CM, Fan G, Wong PY, Kren BT and Steer CJ (1998) Ursodeoxycholic acid may inhibit deoxycholic acidinduced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 4, 165-178 crossref(new window)

Lukivskaya O, Patsenker E and Buko VU (2007) Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci 80, 2397-2402 crossref(new window)

Quintero P, Pizarro M, Solis N et al (2014) Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. J Physiol Biochem 70, 667-674 crossref(new window)

Nie B, Park HM, Kazantzis M et al (2012) Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology 56, 1300-1310 crossref(new window)

Castro RE, Ferreira DM, Afonso MB et al (2013) miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human nonalcoholic fatty liver disease. J Hepatol 58, 119-125 crossref(new window)

Postic C and Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118, 829-838 crossref(new window)

Pathil A, Mueller J, Warth A, Chamulitrat W and Stremmel W (2012) Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 55, 1369-1378 crossref(new window)

Ye R and Scherer PE (2013) Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2, 133-141 crossref(new window)

van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM and Vanberge-Henegouwen GP (1997) Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 32, 369-373 crossref(new window)

Roda E, Azzaroli F, Nigro G et al (2002) Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis 34, 523-527 crossref(new window)

Tsuchida T, Shiraishi M, Ohta T, Sakai K and Ishii S (2012) Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism 61, 944-953 crossref(new window)

Lee JM, Gang GT, Kim DK et al (2014) Ursodeoxycholic acid inhibits liver X receptor alpha-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. J Biol Chem 289, 1079-1091 crossref(new window)

Mueller M, Thorell A, Claudel T et al (2015) Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 62, 1398-1404 crossref(new window)

Link JC, Chen X, Prien C et al (2015) Increased High-Density Lipoprotein Cholesterol Levels in Mice With XX Versus XY Sex Chromosomes. Arterioscler Thromb Vasc Biol 35, 1778-1786 crossref(new window)

Voshol PJ, Haemmerle G, Ouwens DM et al (2003) Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. Endocrinology 144, 3456-3462 crossref(new window)

Nunes PM, Jones JG, Rolo AP, Palmeira CM and Carvalho RA (2011) Ursodeoxycholic acid treatment of hepatic steatosis: a (13)C NMR metabolic study. NMR Biomed 24, 1145-1158 crossref(new window)

Chung HY, Cesari M, Anton S et al (2009) Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 8, 18-30 crossref(new window)

Shoelson SE, Lee J and Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116, 1793-1801 crossref(new window)